Advertisement

Organisation › Details
Evotec SE (FSE: EVT, MDA X/TecDAX)
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. *
![]() |
Start | 2019-04-01 restructured |
Group | Evotec (Group) | |
Predecessor | Evotec AG (FSE: EVT, TecDAX) | |
![]() |
Industry | drug discovery technology |
Industry 2 | drug discovery services | |
![]() |
Person | Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey) |
Person 2 | Spillner, Enno (Evotec 201607– CFO before 4SC CEO + CFO before BioM Venture Capital GmbH) | |
![]() |
Region | Hamburg |
Country | Germany | |
Street | 7 Essener Bogen | |
City | 22419 Hamburg | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | F: 1,001 to 5,000 (2019-12-31) |
Currency | EUR | |
Annual sales | 446,437,000 (revenues, consolidated (2019) 2019-12-31) | |
Profit | 37,228,000 (2019-12-31) | |
Cash | 277,034,000 (2019-12-31) | |
* Document for �About Section�: Evotec AG. (5/31/18). "Press Release: Evotec Forms Academic Bridge »LAB591« with Arix Bioscience and Fred Hutchinson Cancer Research Center". Hamburg. | ||
Record changed: 2021-02-11 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for Evotec (Group)
- [1] Evotec SE. (2/9/21). "Press Release: Evotec and Related Sciences Enter Integrated Drug Discovery and Development Partnership". Hamburg....
- [2] Evotec SE. (12/21/20). "Press Release: Evotec Partners with Alloy Therapeutics to Expand Its Antibody Discovery Platform". Hamburg....
- [3] Evotec SE. (12/17/20). "Press Release: Evotec Achieves Key Milestones in Its Collaboration with Bristol Myers Squibb on Targeted Protein Degradation". Hamburg....
- [4] Evotec SE. (12/9/20). "Press Release: Evotec and Sartorius Partner with Start-up Curexsys on iPSC-based Exosome Approach". Hamburg....
- [5] Evotec SE. (11/24/20). "Press Release: Evotec and Rappta Therapeutics Enter Discovery and Development Partnership Focused on Oncology target". Hamburg....
- [6] Evotec SE. (11/17/20). "Press Release: Evotec and Storm Therapeutics Leverage INDiGO Platform to Progress Oncology Project towards Clinical Studies". Hamburg....
- [7] Eternygen GmbH. (10/26/20). "Press Release: Eternygen Announces the First Closing of its Series A2 Funding Round". Berlin....
- [8] Evotec SE. (10/13/20). "Press Release: Mubdala Investment Company and Novo Holdings A/S Invest €250m in Evotec SE". Hamburg....
- [9] Evotec SE. (10/8/20). "Press Release: Evotec Achieves Milestone in Neurodegeneration Collaboration with Bristol Myers Squibb". Hamburg....
- [10] Evotec SE. (9/14/20). "Press Release: Evotec and BIOASTER Partner to Build a Technology and Innovation Hub in Lyon". Hamburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top